Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...
When killer T cells of our immune system divide, they normally undergo asymmetric cell division (ACD): Each daughter cell inherits different cellular components, which drive the cells toward divergent ...
CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results